Navigation Links
Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
Date:1/8/2008

cancer and study participants will be randomized in one of two arms of the trial (1:1), to receive either NKTR-102 and cetuximab or standard irinotecan and cetuximab. The Phase 2b stage is expected to begin in mid-year 2008 and will be conducted in over 40 centers worldwide. The primary endpoint of the Phase 2b trial is progression-free survival. Secondary endpoints include response rate, response duration, overall survival, standard pharmacokinetics, and incidence of toxicities, including diarrhea and neutropenia.

Prior Data Presentations for NKTR-102

Peer-reviewed presentations of preclinical study results for NKTR-102 were presented at ECCO 14 and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the fall of 2007. These presentations can be found at: http://www.nektar.com/wt/page/nktr102media

About NKTR-102

Nektar is developing NKTR-102, a PEGylated form of irinotecan, which was invented by Nektar using its world-leading small molecule PEGylation technology platform. The product is currently in Phase 2 clinical development. Irinotecan, also known as Camptosar, is an important chemotherapeutic agent used for the treatment of solid tumors, including colorectal and lung cancers. By applying Nektar's small molecule PEGylation technology to irinotecan, NKTR-102 may prove to be a more powerful and tolerable anti-tumor agent.

Preclinical studies show that treatment with NKTR-102 results in significant suppression of tumor growth in an irinotecan-resistant mouse colorectal tumor model. Administration of NKTR-102 in an animal model results in a significantly improved time-concentration profile for the active metabolite of irinotecan as compared to treatment with standard irinotecan.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its indu
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
2. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
7. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)...  In anticipation of the upcoming MEDevice San Diego ... the first time. Industry Overview: Medtech & Life Sciences ... snapshot of San Diego,s critical involvement ... latest employment statistics to current venture capital investment trends, the ... such a vital part of the global medical device ...
(Date:8/28/2014)... 28, 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite leadership ... has published a case study highlighting one ... Course . In September and October 2014, Academy Leadership ... Albuquerque , Indianapolis , Salt Lake ... - http://photos.prnewswire.com/prnh/20140828/140814 Leadership training ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... SEATTLE, Aug. 22 Vical Incorporated (Nasdaq:,VICL) announced ... vaccine Phase 2a,clinical trials, using a plasmid DNA ... and manufactured by Vical, reinforced previously,reported Phase 1 ... was safe and well-tolerated, and was effective in ...
... - Alfacell Corporation,(Nasdaq: ACEL ) today announced ... Oncology (2007; Vol. 31, Issue 3: 663-669) reports ... cell types and tumor cell lines. The observed ... cytotoxic effect on cancer cells and,mechanistic synergism with ...
Cached Medicine Technology:Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 2Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 3
(Date:8/29/2014)... RBS Reputation Management has brought a new ... service is to help those individuals and organizations that are ... Book. The service would push down the ranking of Scam ... fully invisible on Google. , RBS Reputation Management provides ... asked how company can provide guarantee of results with the ...
(Date:8/29/2014)... August 29, 2014 Los Angeles ... offering mini implants to area patients. With this treatment, ... of long-term teeth shifting and loss of appearance. Although ... dental implants , their smaller size allows for ... and easier recovery. Once placed, mini implants can be ...
(Date:8/29/2014)... 2014 "After reading a study that said ... often, I decided that there needed to be a way ... said a concerned inventor from Sikestons, Mo. , The Stand ... It builds endurance and keeps the user from sitting too ... use and producible in design variations, it's ideal for anyone ...
(Date:8/29/2014)... India (PRWEB) August 29, 2014 Ethane ... has recently launched a new service named HTML web ... research based service. Before tailoring the service, Ethane Web ... by other companies. The company has done its best ... impeccable and able to deliver outstanding results to clients. ...
(Date:8/29/2014)... and basic life support (BLS) videos available on ... health guidelines, according to a new study published ... for the Australasian College for Emergency Medicine (ACEM). ... cardiac arrest are known to improve survival for,victims. ... put together the study, which reviewed educational videos ...
Breaking Medicine News(10 mins):Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:Dental Implants Dentist, Kevin Sands DDS, Is Now Offering Mini Implants 2Health News:Ethane Web Technologies Launches a New Web Design Service 2
... UC Irvine Medical Center recently received a Silver Medal of ... for its role in supporting organ and tissue donation. ... the highest-performing 12-month period between Oct. 1, 2008, and March ... commended in the seven-county Greater Los Angeles area served by ...
... THURSDAY, Dec. 2 (HealthDay News) -- The suicide rate among ... than among civilian women, a new study has found. ... between 2004 and 2007. In the 18-to-34 age group, there ... 33,257,362 nonveterans. That suicide rate amounted to one out ...
... arthritis drug reduces the incidence of non-melanoma skin cancers ... to a study published this week in the ... COX-2 inhibitor celecoxib (brand name Celebrex), which is currently ... acute pain in adults led to a 62 percent ...
... a lawyer, a politician, a professional athlete, an environmentalist or ... some researchers. Still others say the driving force is our ... But a new child-development theory bridges those two models, says ... Holden,s theory holds that the way a child turns out ...
... early in life led to an accumulation of abdominal fat and ... according to new research. Animals exposed to the fine-particulate air ... and higher blood sugar levels than did animals eating the same ... the polluted air for six hours a day, five days a ...
... From microscopy to computer tomography (CT) scans, imaging ... research, but obtaining high-quality images often requires advanced ... a project which launches its preparatory phase today, ... access to state-of-the-art imaging technologies at all levels ...
Cached Medicine News:Health News:UC Irvine Medical Center is recognized for its commitment to organ donation 2Health News:Female Vets Much More Likely to Commit Suicide, Study Finds 2Health News:Widely used arthritis pill protects against skin cancer 2Health News:Widely used arthritis pill protects against skin cancer 3Health News:Beyond nature vs. nurture: Parental guidance boosts child's strengths, shapes development 2Health News:Beyond nature vs. nurture: Parental guidance boosts child's strengths, shapes development 3Health News:Beyond nature vs. nurture: Parental guidance boosts child's strengths, shapes development 4Health News:Polluted air increases obesity risk in young animals 2Health News:Polluted air increases obesity risk in young animals 3Health News:Better imaging from bench to bedside 2
... fast, precise patternless edge for a perfect ... ALE-X1. The latest advance in lens processing ... and functions. High-speed processing, a diamond luster ... precise three-dimensional frame tracing via the automated ...
... mapping software system enhances clinical evaluations with ... corneal maps. The system offers an enlarged ... refractive and keratometric data, and peripheral keratometric ... subclinical keratoconus as well as pre and ...
... Ergonomic, computer-integrated, flexibility, combined with the ... contemporary styling, make the new Topcon ... highly competitive 21st Century practice environments: ... lane fits comfortably in an 8' ...
... Topcon combines the benefits of IMAGEnet Lite, ... a Compaq PC with the Topcon TRC-NW6 ... use color fundus screening package. The system ... software with Topcons Non-Mydriatic retinal camera allowing ...
Medicine Products: